Less Ads, More Data, More Tools Register for FREE
Sponsored Content
Don't want ads? Click here
Sponsored Content
Don't want ads? Click here

Pin to quick picksIQ-AI Share News (IQAI)

  • There is currently no data for IQAI

Watchlists are a member only feature

Login to your account

Timelines are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: AIQ revenue soars; Mobius Investment net assets drop

Tue, 28th Feb 2023 19:40

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

AIQ Ltd - Cayman Islands-based firm focused on acquiring and developing e-commerce sector businesses - Revenue in the year that ended October 31 multiplies to GBP498,388 from GBP61,863 the year prior. Pretax loss narrows to GBP640,906 from GBP1.2 million. Attributes this primarily to the delivery of the DeFi DEX contract, which accounted for GBP438,824 of revenue. "We entered the year having decided to pivot to focus on the provision of IT consultancy services to customers who deliver blockchain technology and digital assets, such as NFTs. We had some success during 2022 in capitalising on the lack of IT solutions providers in Asia that specialise in the delivery of blockchain platforms, including forming partnerships with key solutions providers and completing a contract to project manage the supply of a decentralised finance exchange to a customer based in Australia," Chair Harry Chathli comments.

----------

Mobius Investment Trust PLC - investment company - Net asset value per share stands at 134.2 pence as at November 30, down 13% from 153.4p on the same date a year prior. Share price as at November 30 falls 15% to 131.0 pence from 154.5p on the same date a year before. Notes how unprecedented the year has been in terms of political and economic events, with the war in Ukraine and China's hard stance on Covid-19 pushing the recovery back. Records a total NAV return of 12.3%. Declares a final dividend of 1.20p, up sharply from 0.35p.

----------

IQ-AI Ltd - Jersey-based medical services firm - Says gallium maltolate, a novel oral agent, was granted orphan drug designation by the US Food & Drug Administration for the treatment of glioblastoma multiforme brain cancer. Intends to "take full advantage" of the benefits orphan designation offers. This includes assistance in the drug development process, tax credits, grant opportunities, and seven years of market exclusivity post-approval. Notes that the status is independent from the overall approval process by the FDA.

----------

Kazera Global PLC - diamond and rare earths explorer in South Africa and Namibia - Says it will not be able to publish its annual report and accounts for the year that ended June 30 at the end of February. Says that trading on AIM will continue to be suspended until the publication of the results. Continues to make progress with its heavy mineral sands and diamond operations now in production. Confirms that it has paid off all outstanding debt to the former directors and loan providers and now sits in a healthy net cash position.

----------

Uru Metals Ltd - Toronto-based investor and mine project developer - Says Richard Montjoie was appointed as interim Chief Executive of Zeb Nickel. Says he has been with Zeb for over a decade. Adds that he played a pivotal role in the exploration efforts that have led to the discovery of several nickel deposits. Uru has just shy of 75% stake in Zeb Nickel.

----------

Appreciate Group PLC - Merseyside, England-based multi-retailer redemption product provider to corporate and consumer markets - Says it takeover by Paypoint PLC is complete, as the court-sanctioned the scheme of arrangement between Appreciate and relevant Appreciate shareholders. PayPoint agreed to buy Appreciate in a deal which valued the company at around GBP83 million. PayPoint will pay 33 pence in cash and 0.019 of a new PayPoint share for each Appreciate share.

----------

DP Aircraft I Ltd - Guernsey-based aircraft leasing company - Agrees on new terms with its lending banks for in a second amendment and restatement to its loan agreement for both aircraft loans. Fixes interest rates for tranche 1 and tranche 2 for DP Aircraft III tranche 1 at 5.26% and tranche 2 at a fixed balloon interest rate of 6.61%. Fixes DP Aircraft IV tranche 1 at 5.42% and tranche 2 at a fixed balloon interest rate of 6.89%. Says that the aggregated final balloon payment in 2026 is forecast to amount to approximately USD69.5 million based on the new terms.

----------

Hambro Perks Acquisition Co Ltd - Hambro Perks-sponsored special purpose acquisition vehicle - Says 93% of its shareholders approved the extension the business combination deadline to November 30. "We are delighted to have received shareholder approval for the extension, which highlights the confidence and support of our investors. We are encouraged by the positive conversations we are having with interested companies for a possible business combination and look forward to updating the market in due course," Chief Executive Dominic Perks comments.

----------

By Abby Amoakuh, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
10 Jan 2024 11:48

IQ-AI falls after subsidiary notes launch of treatment access scheme

(Alliance News) - IQ-AI Ltd shares fell on Wednesday, after it said its subsidiary Imaging Biometrics LLC is launching an intermediate population cohort expanded access programme for oral gallium maltolate.

Read more
19 Dec 2023 17:00

IQ-AI firm gets US FDA fast-track status for oral gallium maltolate

(Alliance News) - IQ-AI Ltd on Tuesday said the US Food & Drug Administration has granted 'fast-track" designation for oral gallium maltolate, which is its subsidiary Imaging Biometrics LLC's therapeutic for the treatment of adult patients with relapsed or refractory glioblastoma.

Read more
5 Dec 2023 11:49

IQ-AI stock rises on positive interim results from glioblastoma trial

(Alliance News) - IQ-AI Ltd on Tuesday reported positive results from Phase 1 of an on-going study for its investigational monotherapy oral gallium maltolate.

Read more
8 Nov 2023 12:04

IQ-AI says Imaging Biometrics submits paediatric rare disease request

(Alliance News) - IQ-AI Ltd on Wednesday said its wholly-owned subsidiary Imaging Biometrics LLC has submitted a paediatric rare disease request to the US Food & Drug Administration for its gallium maltolate therapy.

Read more
18 Oct 2023 17:11

IN BRIEF: IQ-AI subsidiary "central" to "landmark" brain cancer study

IQ-AI Ltd - St Helier, Jersey-based medical services firm focused on cancer treatment - Notes its wholly-owned subsidiary, Imaging Biometrics LLC (IB), has announced the results of a "landmark" study. Says the study represents the first large-scale characterization of the invasive tumour margins of high-grade glioma using multi-regional genomic/transcriptomic sequencing with spatially matched MRI measurements in glioma. High-grade glioma is a deadly brain cancer. Explains that Imaging Biometrics' IB Neuro's dynamic susceptibility contrast magnetic resonance imaging software was central to the study.

Read more
9 Oct 2023 12:09

IN BRIEF: IQ-AI subsidiary wins orphan drug designation from US FDA

IQ-AI Ltd - St Helier, Jersey-based medical services firm focused on cancer treatment - Wholly-owned subsidiary Imaging Biometrics LLC is granted an orphan drug designation from the US Food & Drug Administration for gallium maltolate for the treatment of atypical teratoid rhabdoid tumour. Notes this is the second orphan designation granted to gallium maltolate this year.

Read more
8 Sep 2023 10:25

IQ-AI notes vindication of subsidiary's reduced gadolinium approach

(Alliance News) - IQ-AI Ltd on Friday noted that studies by its subsidiary Imaging Biometrics LLC validated the dosing approach of Imaging's MRI-focused IB Neuro.

Read more
18 Aug 2023 12:17

IQ-AI shares jump on subsidiary's GE Healthcare deal

(Alliance News) - IQ-AI Ltd on Friday said its wholly-owned subsidiary Imaging Biometrics LLC has signed a deal with GE HealthCare Technologies Inc.

Read more
17 Aug 2023 11:21

IQ-AI interim loss narrows amid higher revenue, lower expenses

(Alliance News) - IQ-AI Ltd on Thursday announced a slightly lower loss for the six months to June 30, as revenue was up and administrative expenses were lower.

Read more
19 Jul 2023 10:45

IN BRIEF: IQ-AI subsidiary's app adopted by US medical college

IQ-AI Ltd - Jersey-based medical services firm focused on cancer treatment - Says subsidiary Imaging Biometrics LLC's handheld application IB Nimble has been adopted by the Medical College of Wisconsin's Orthopedic Department for use in bone metastases treatment. IB Nimble's designer, Joseph Bovi, is professor of radiation oncology & neurosurgery at MCW. The application was originally designed to help treat brain metastases. IQ-AI says it "provides real-time collaboration amongst multi-disciplinary teams" to "provide optimised treatments faster". Josh McComack, Imaging Biometrics' director of software engineering, says the new installation "demonstrates that IB Nimble is ready for widespread deployment."

Read more
13 Jul 2023 11:36

IN BRIEF: IQ-AI granted orphan drug designation for Gallium Galtolate

IQ-AI Ltd on Thursday - Jersey-based incubator of software and other tools for the treatment of cancer - IQ-AI subsidiary Imaging Biometrics LLC has been granted an orphan drug designation for Gallium Galtolate for the treatment of paediatric glioblastoma multiforme, or GBM, by the US Food & Drug Administration. Says GBM is the most common and aggressive primary brain tumour in adults and children. Imaging Biometrics' application to the FDA was first submitted in April. In June, two pre-clinical studies showed oral GaM inhibits brain tumour growth in children, and the results were consistent with previous work conducted in the Schmainda Lab at the Medical College of Wisconsin.

Read more
27 Jun 2023 11:47

IN BRIEF: IQ-AI notes Gallium Moltate studies on tumour growth

IQ-AI Ltd - Jersey-based medical services firm - Says subsidiary Imaging Biometrics LLC's two new pre-clinical studies show oral Gallium Maltolate inhibits brain tumour growth in children. Says the results are consistent with previous work conducted in the Schmainda Lab at the Medical College of Wisconsin. This follows IB's application for Orphan Drug Designation to the US Food & Drug Administration back in April for the use of GaM in pediatric brain tumours. Notes application is currently under review.

Read more
23 May 2023 16:12

TRADING UPDATES: Harworth optimistic on 2027; Plexus extends agreement

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
16 May 2023 15:53

UK shareholder meetings calendar - next 7 days

Read more
26 Apr 2023 14:43

EARNINGS SUMMARY: Third Point Investors NAV per share drops by quarter

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.